Market Overview

Teva, Handok to Establish Business Venture in South Korean Pharmaceutical Market


Teva Pharmaceutical (NYSE: TEVA) and Handok
Pharmaceuticals Co announced today their agreement
to establish a business venture in South Korea, allowing Teva to gain
entrance into the Korean pharmaceutical market, currently valued at
approximately USD 14 billion. Under the terms of the agreement, Teva
will contribute its global resources, with responsibilities for
manufacturing and supplying a wide range of affordable and innovative
medicines. Handok's primary responsibility will be in sales and
marketing, distribution, and regulatory affairs. Teva will have a
controlling stake in the new business venture, with a profit split of
51%/49% to Teva and Handok, respectively.

"This is another significant step in our strategy to expand

See full press release

Posted-In: News Guidance Contracts Global


Related Articles (TEVA)

View Comments and Join the Discussion!

Partner Center